Piper Sandler analyst Matt O’Brien raised the firm’s price target on TransMedics (TMDX) to $125 from $105 and keeps an Overweight rating on the shares. The firm notes the company reported Q1 results that beat on the top and bottom lines. Management also raised full year sales guidance by more than the beat. Piper expects the guide will remain a key topic amongst investors, particularly as competitors enter TransMedics’ crucial liver market later this year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- TransMedics Group: Balancing Strong Q1 Performance with Growth and Margin Concerns
- TransMedics Group: Strong Performance with Cautious Outlook Amid Competitive and Reimbursement Uncertainties
- TransMedics Reports Strong Q1 2025 Financial Results
- TransMedics Group: Strong Financial Performance and Promising Growth Prospects Drive Buy Rating
- TransMedics reports Q1 EPS 70c, consensus 24c